Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

58 results about "Quantitative proteomics" patented technology

Quantitative proteomics is an analytical chemistry technique for determining the amount of proteins in a sample. The methods for protein identification are identical to those used in general (i.e. qualitative) proteomics, but include quantification as an additional dimension. Rather than just providing lists of proteins identified in a certain sample, quantitative proteomics yields information about the physiological differences between two biological samples. For example, this approach can be used to compare samples from healthy and diseased patients. Quantitative proteomics is mainly performed by two-dimensional gel electrophoresis (2-DE) or mass spectrometry (MS). However, a recent developed method of quantitative dot blot (QDB) analysis is able to measure both the absolute and relative quantity of an individual proteins in the sample in high throughput format, thus open a new direction for proteomic research. In contrast to 2-DE, which requires MS for the downstream protein identification, MS technology can identify and quantify the changes.

Capillary monolithic column spray needle and preparation method and application thereof

The invention relates to an interface for microcolumn liquid chromatogram and mass spectrum, in particular to a capillary monolithic column spray needle. The capillary monolithic column spray needle comprises a capillary pipe, the capillary pipe is filled with monolithic material, a needle head used for electron spray extend at one end of the capillary pipe to form a capillary monolithic column spray needle, then the capillary monolithic column spray needle is connected to the tail end of a capillary separating column through a two-way pipe and the voltage used for electron spray is applied to the two-way pipe. The invention has the main advantages that because the dead volume existing in an electron spray needle in the combined use of the microcolumn liquid chromatography and the mass spectrum and the electron spray needle is eliminated, the capillary monolithic column spray needle eliminates the disturbance and the mixing action of the dead volume to the microcolumn liquid chromatography is eliminated, greatly enhances the separating capacity and the repeatability of the microcolumn liquid chromatography and represents superior performance to the commercial capillary electron spray needle in the quantitative proteomics; and in addition, because the monolithic column material exists in the capillary monolithic column spray needle, the problem that the electron spray needle is easy to be blocked during the separation and the analysis process is solved and the service life of the electron spray needle is greatly prolonged.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI

Data analysis method for quantitative methods for b, y fragment ion pairs on second-level mass spectra from peptide fragments of same mass on first-level mass spectra

InactiveCN102809600AThe impact of correct certainty is reducedAdd optimization moduleMaterial analysis by electric/magnetic meansMass spectrometryQuantitative methodology
The invention relates to the technical field of proteomics, in particular to a data analysis method for quantitative methods for b, y fragment ion pairs on second-level mass spectra from peptide fragments of same mass on first-level mass spectra. The method is written by using a Matlab language and runs in a Matlab interface, and qualitative information of peptide fragments and protein is obtained by making ratio through extracting peak intensity information of b, y fragment ion pairs on tandem mass spectra and on the basis of a qualitative result of protein obtained by a SEQUEST search engine. According to the method, an optimization module for 'spectrogram resolution' is also added, so that the influence of a b, y fragment ion pair fragmentation spectrogram on the qualitative correctness of the peptide fragments is reduced. According to the method, a z statistical magnitude is also constructed to calculate the significance of quantitative protein, so that a reference evidence is provided for determining up-regulated and down-regulated changed protein in a practical sample. The invention provides a universal, open and accurate quantitative analysis means for development and application of novel quantitative proteomics methods for the b, y fragment ion pairs on second-level mass spectra from peptide fragments of same mass on first-level mass spectra.
Owner:FUDAN UNIV

Application of anti-PDCD4 (Programmed Cell Death 4) antibody in preparation of detection reagent for predicting personalized medicine sensitivity of paclitaxel or derivative drug of paclitaxel

The invention discloses application of an anti-PDCD4 (Programmed Cell Death 4) antibody in preparation of a detection reagent for predicting personalized medicine sensitivity of paclitaxel or a derivative drug of paclitaxel. The variation of protein abundance of whole cells in tumor cells treated by paclitaxel is analyzed by using a quantitative proteomics technology, the results shows that paclitaxel reduces the expression level of PDCD4 and the sensitivity of the tumor cells to paclitaxel is in positive correlation with the expression level of PDCD4 in cells. PDCD4 in the tumor cells is subject to gene silencing or overexpression and the result further proves that the sensitivity of the cells to paclitaxel is in positive correlation with the expression level of PDCD4 in the cells. Meanwhile, researches on survival prognosis of clinical lung cancer patients shows that under the same paclitaxel combined adjuvant chemotherapy, the survival prognosis of patients with low expression level of PDCD4 is poor and the survival time of patients with high expression level of PDCD4 is long. Based on the research results, the invention provides a reference index and a detection and application method for guiding personalized medicine of paclitaxel or the derivative drug (such as docetaxel) of the paclitaxel.
Owner:HARBIN MEDICAL UNIVERSITY

Method for monitoring and qualification of 15N metabolic labeled protein in combination with mass spectrum parallel reaction

PendingCN109444279AIncreased productivity in parallel reaction monitoring quantitationLow costComponent separationProtein markersPeptide ions
The invention discloses a method for monitoring and qualification of 15N metabolic labeled protein in combination with mass spectrum parallel reaction. 15N metabolic labeled internal reference proteincan accurately reflect the structure and the state of endogenous protein to be detected, has the same enzymolysis efficiency with the protein to be detected, solves the problem that internal reference peptide ion strength signals are affected by protease digestion, co-elute matrix, sample composition and instrument status during mass spectrum selection, tracking and quantification to cause nonreproducibility, and meanwhile improves the efficiency of monitoring and qualification of mass spectrum parallel reaction; in addition, the method can produce various quantitative polypeptide used for parallel reaction monitoring, improves the qualification accuracy, reduces the cost for synthesizing polypeptide, can be applied to quantitative proteomic research and detection of protein markers, andhas great help in medical diagnosis, environmental health, food safety inspection and judicial expertise.
Owner:北京蛋白世界生物科技有限公司

Isotopic labeling of higher organisms

The invention generally relates to metabolic labeling of a target organism with a stable isotope. In a first aspect, the present invention relates to a method for metabolic labeling of a target organism with a stable isotope. The present invention also relates to a method of producing a diet for metabolic labeling of a target organism and to a diet composition for metabolic labeling of a target organism. In a further aspect the invention describes the use of the diet composition according to the present invention for producing a metabolically labeled target organism as a reference for a quantitative proteomic approach. The present invention also relates, in a further aspect, to the use of a diet composition for pulse SILAC labeling. The present invention also relates to the use of a target organism labeled by the method according to the first aspect of the present invention as a spike-in standard in quantitative proteomics approaches.
Owner:SILANTES

Systems and methods for proteomic activity analysis using dna-encoded probes

Systems, kits, and methods for detecting and quantifying proteomic activity using DNA-encoded probes are provided, where the proteomic activity may be enzymatic activity or ligand binding affinity. Such systems and methods encode quantitative proteomic activity information into DNA sequence populations and utilize DNA-linked substrates or ligands as activity probes. The systems, kits, and methods that are directed to detecting ligand affinity further include crosslinking steps to ensure the integrity of the DNA-linked ligands during purification and washing. Signal detection involves the chemical manipulation of a probe population downstream of sample exposure and application of purifying, selective pressure for desired products. Selection-induced changes in DNA abundance between the initial pool and the purified pool indicate sample activity.
Owner:PURDUE RES FOUND

Amniotic fluid proteomics detection method of premature delivery prediction marker and application thereof

PendingCN113933407ARising death rateRising incidenceComponent separationBiological testingLiquid chromatography mass spectroscopyFull Term Birth
The invention discloses an amniotic fluid proteomics detection method of a premature delivery prediction marker and application thereof and relates to the technical field of genetic engineering. The method comprises the following steps of obtaining amniotic fluid differential expression proteins of premature delivery patients (excluding cervical factors) and full-term delivery normal control pregnant women through a liquid chromatography-mass spectrometry method; carrying out GO functional characterization and KEGG pathway analysis on the differentially expressed protein; and verifying the selected candidate protein by using an enzyme-linked immunosorbent assay. The TMT-labeled quantitative proteomics method is used for comparing protein expression differences in amniotic fluid of premature delivery patients (excluding cervical factors) and amniotic fluid of full-term delivery pregnant women. Bioinformatics analysis shows that 44 differential expression proteins and 9 main ways may participate in premature delivery. Subsequent ELISA detection proves that SEPRIN-A1 and IGFBP-4 have significant correlation with premature delivery, and a new thought and approach are provided for prevention and mechanism clarification of premature delivery.
Owner:MATERNAL & CHILD HEALTH CARE HOSPITAL OF SHANDONG PROVINCE SHANDONG UNIV

Methods and biomarker for evaluating cancer metastasis, pharmaceutical composition for inhibiting cancer metastasis, and method for analyzing secretome

The invention relates to methods and biomarker for evaluating cancer metastasis, pharmaceutical composition for inhibiting cancer metastasis, and method for analyzing secretome. By combining a hollow fiber cartridge (HFC) culture system with quantitative proteomics technology, cancer metastasis-related secrectomes can be found. Furthermore, this is the first time to use PARK7 as a biomarker for judging the process of non-small cell lung cancer.
Owner:NAT CHENG KUNG UNIV

Application of NSrp70 gene in preparation of tumor metastasis related pharmaceutical preparations

The invention belongs to the technical field of biomedical engineering, and relates to a new application of an NSrp70 gene, in particular to an application of the NSrp70 gene in preparation of tumor metastasis related pharmaceutical preparations. The nuclear protein quantitative proteomics analysis is carried out on breast cancer cells; the results show that the nuclear speckle protein NSrp70 shows low expression in breast cancer cells with high metastasis potential, the in-vitro and in-vivo experiments prove that the interference of NSrp70 can significantly promote the metastasis ability of the cells, and overexpression of the gene can significantly inhibit the metastasis ability of the cells; the NSrp70 can inhibit cell EMT by inhibiting a TGF beta signal path, and finally breast cancermetastasis is inhibited; the NSrp70 can be used as a new molecular target and a molecular marker in a breast cancer metastasis process to be applied to preparation of breast cancer metastasis relatedmedicaments, including preparation of a detection kit for detecting cancer metastasis, a medicine for inhibiting cancer metastasis and a medicine for inhibiting a cancer metastasis related signal path. The novel application is helpful for preventing and inhibiting breast cancer metastasis and benefiting cancer patients.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products